-20 -10 0 10 20 30 40 50 60 -20 -10 0 10 20 30 40 50 60 Time (min)

STRESSED CONTROLS SSR149415 (30 mg/kg po)


Fig. 6. Effects of the Vlb receptor antagonist, SSR149415, on autonomic markers of the stress response produced by restraint as measured by radiotelemetry. It consists notably of significant elevations of blood pressure and heart rate. SSR149415 and diazepam were administered 60 and 30min prior to restraint, respectively. Data represent mean ± S.E.M. * /><0.05, **P<0.0l (vs stressed controls).

Studies using SSR149415 targeted to specific regions such as the amygdala, septum or hippocampus, are in progress. They should help to clarify the involvement of the Vib receptor in anxiety and depression. In conclusion, the development of nonpeptide V,b receptor antagonists opened a new era for examining the role of AVP in animal models of stress, and may provide a novel avenue for the treatment of affective disorders.


Abelson, J.L, Le Mellédo, J.M. and Bichet, D.G. (2001) Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. Neuropsychopharmacology, 24: 161-169. Aguilera, G. (1994) Regulation of pituitary ACTH secretion during chronic stress. Front. Neuroendocrinol, 15: 321-350.

Aguilera, G. and Rabadan-Diehl, C. (2000) Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul. Pept, 96: 23-29.

Alescio-Lautier, B, Metzger, D. and Soumireu-Mourat, B. (1993) Central behavioral effects of vasopressin: point and perspectives. Rev. Neurosci, 4: 239-266.

Antoni, F.A. (1993) Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front. Neuroendocrinol, 14: 76-122.

Bale, T.L, Davis, A.M., Auger, A.P, Dorsa, D.M. and McCarthy, M.M. (2001) CNS region-specific oxytocin receptor expression: Importance in regulation of anxiety and sex behavior. J. Neurosci, 21: 2546-2552.

Blanchard, D.C, Sakai, R.R, McEwen, B, Weiss, S.M. and Blanchard, R.J. (1993) Subordination stress: Behavioral, brain and neuroendocrine correlates. Behav. Brain Res, 58: 113-121.

Blanchard, R.J, Griebel, G, Gully, D, Serradeil-Le Gal, C, Markham, C, Yang, M. and Blanchard, D.C. (2002)

Effects of the Vlb antagonist, SSR149415 and the CRF, antagonist, SSR125543A in the VBS are suggestive of anti-depressant-like activity. Program No. 307.3. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, CD-ROM.

Blanchard, R.J, Griebel, G, Henrie, J.A. and Blanchard, D.C. (1997) Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci. Biobehav. Rev, 21: 783-789.

Bremner, J.D, Krystal, J.H., Southwick, S.M. and Charney, D.S. (1996a) Noradrenergic mechanisms in stress and anxiety. 1. Preclinical studies. Synapse, 23: 28-38.

Bremner, J.D, Krystal, J.H, Southwick, S.M. and Charney, D.S. (1996b) Noradrenergic mechanisms in stress and anxiety.2. Clinical studies. Synapse, 23: 39-51.

Caffe, A.R., van Leeuwen, F.W. and Luiten, P.G.M. (1987) Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus. J. Comp. Neurol, 261: 237-252.

Chrousos, G.P. and Gold, P.W. (1998) A healthy body in a healthy mind - and vice versa - the damaging power of "uncontrollable" stress. J. Clin. Endocrinol. Metab, 83: 1842-1845.

Dantzer, R. and Bluthe, R.M. (1992) Vasopressin involvement in antipyresis social communication, and social recognition: a synthesis. Crit. Rev. Neurobiol, 6: 243-255.

Davis, M„ Falls, W.A., Campeau, S. and Kim, M. (1993) Fear-potentiated startle: A neural and pharmacological analysis. Behav. Brain Res, 58: 175-198.

De Vries, G.J. and Buijs, R.M. (1983) The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Res, 273: 307-317.

De Wied, D. (1965) The influence of posterior and intermediate lobe of the pituitary and pituitary peptides on the maintenance of a conditioned avoidance response in rats. Int. J. Neuropharmacol, 4: 157-167.

De Wied, D. (1970) Preservation of a conditioned avoidance response by lysine vasopressin. J. Endocrinol, 48: xlv-xlvi.

Dinan, T.G., Lavelle, E„ Scott, L.V, Newell-Price, J, Medbak, S. and Grossman, A.B. (1999) Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: Evidence of enhanced vasopressinergic responsivity. J. Clin. Endocrinol. Metab, 84: 2238-2240.

Engelmann, M, Wotjak, C.T., Neumann, I, Ludwig, M. and Landgraf, R. (1996) Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci. Biobehav. Rev, 20: 341-358.

Funk, D. and Stewart, J. (1996) Role of catecholamines in the frontal cortex in the modulation of basal and stress-induced autonomic output in rats. Brain Res.. 741: 220-229.

Griebel, G. (1999) Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther, 82: 1-61.

Griebel, G. and Sanger, D.J. (1999) The mouse defense test battery: an experimental model of different emotional states. In: M. Haug and R.E. Whalen (Eds.), Animal Models of Human Emotion and Cognition, American Psychological Association, Washington, DC, pp. 75-85.

Griebel, G, Simiand, J, Serradeil-Le Gal, C„ Wagnon, J, Pascal, M, Scatton, B„ Maffrand, J.-P. and Soubrie, P. (2002a) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin Vlb receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA, 99: 6370-6375.

Griebel, G, Simiand, J, Steinberg, R, Jung, M, Gully, D„ Roger, P, Geslin, M„ Scatton, B„ Maffrand, J.P. and Soubrie, P. (2002b) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(lS)-2-cyclopropyl- l-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releas-ing factor, receptor antagonist. II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther, 301: 333-345.

Griebel, G, Simiand, J, Steinberg, R, Serradeil-Le Gal. C, Wagnon, J, Pascal, M, Scatton, B, Maffrand, J.P, Le Fur, G. and Soubrie, P. (2002c) Reduced emotionality by the non-peptide vasopressin V]b receptor antagonist, SSR149415, suggest a novel approach for the treatment of stress-related disorders. J. Neuropsychopharmacol., 5 (Suppl. 1): S128.

Hashimoto, S, Inoue, T. and Koyama, T. (1996) Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Psychopharmacology, 123: 182-186.

Holsboer, F. (1999) The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiat. Res, 33: 181-214.

Holsboer, F. and Barden, N. (1996) Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrine Rev., 17: 187-205.

Inoue, T, Tsuchiya, K. and Koyama, T. (1996) Serotonergic activation reduces defensive freezing in the conditioned fear paradigm. Pharmacol. Biochem. Behav, 53: 825-831.

Kitaichi, K, Minami, Y, Amano, M, Yamada, K, Hasegawa, T. and Nabeshima, T. (1995) The attenuation of suppression of motility by triazolam in the conditioned fear stress task is exacerbated by ethanol in mice. Life Sci, 57: 743-753.

Koob, G.F. (1999) Corticotropin-releasing factor, norepinephrine, and stress. Biol. Psychiat, 46: 1167-1180.

Koob, G.F. and Bloom, F.E. (1982) Behavioral effects of neuropeptides: endorphins and vasopressin. Annu. Rev. Physiol, 44: 571-582.

Kopp, C, Vogel, E, Rettori, M.C, Delagrange, P. and Misslin, R. (1999) The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav. Pharmacol, 10: 73-83.

Landgraf, R, Gerstberger, R, Montkowski, A, Probst, J.C, Wotjak, C.T, Holsboer, F. and Engelmann, M. (1995) VI vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J. Neurosci, 15: 4250-4258.

Liebsch, G, Wotjak, C.T, Landgraf, R. and Engelmann, M. (1996) Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci. Lett, 217: 101-104.

Lolait, S.J, O'Carroll, A.M., Mahan, L.C, Felder, C.C, Button, D.C, Young, W.S, III, Mezey, E. and Brownstein, M.J. (1995) Extrapituitary expression of the rat Vlb vasopressin receptor gene. Proc. Natl. Acad. Sci. USA, 92: 6783-6787.

Maki, Y, Inoue, T, Izumi, T, Muraki, I, Ito, K, Kitaichi, Y, Li, X.B. and Koyama, T. (2000) Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Eur. J. Pharmacol, 406: 411—118.

Manning, M. and Sawyer, W.H. (1993) Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J. Recept. Res, 13: 195-214.

McCann, S.M. and Brobeck, J.R. (1954) Evidence for a role of the supraopticohypophyseal system in the regulation of adrenocorticotropin secretion. Proc. Natl. Acad. Sci. USA, 87: 318-324.

McEwen, B.S. (2000) The neurobiology of stress: from serendipity to clinical relevance. Brain Res, 886: 172-189.

Molewijk, H.E, Hartog, K, Vanderpoel, A.M., Mos, J. and Olivier, B. (1996) Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacol-ogy, 128: 31-38.

Morel, A, O'Carroll, A.M., Brownstein, M.J. and Lolait, S.J. (1992) Molecular cloning and expression of a rat Via arginine vasopressin receptor. Nature, 356: 523-526.

Oka, T, Oka, K. and Hori, T. (2001) Mechanisms and mediators of psychological stress-induced rise in core temperature. Psychosom. Med, 63: 476—486.

Olivier, B, Molewijk, E, vanOorschot, R, vanderHeyden, J, Ronken, E. and Mos, J. (1998) Rat pup ultrasonic vocalization: effects of benzodiazepine receptor ligands. Eur. J. Pharmacol, 358: 117-128.

Paranjape, S.B. and Thibonnier, M. (2001) Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. Expert. Opin. Invest. Drugs, 10: 825-834.

Purba, J.S, Hoogendijk, W.J.G, Hofman, M.A. and Swaab, D.F. (1996) Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry, 53: 137-143.

Rowe, W, Viau, V, Meaney, M.J. and Quirion, R. (1995) Stimulation of CRH-mediated ACTH secretion by central administration of neurotensin: evidence for the participation of the paraventricular nucleus. J. Neuroendocrinol, 7: 109-117.

Serradeil-Le Gal, C. (1998) Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR121463A, a new potent and highly selective V2 receptor antagonist. In Zingg (Ed), Vasopressin and Oxytocin, Plenum Press, New York, pp. 427^138.

Serradeil-Le Gal, C, Wagnon, J, Simiand, J, Griebel, G, Lacour, C, Guillon, G, Barberis, C, Brossard, G, Soubrie, P, Nisato, D, Pascal, M, Pruss, R, Scatton, B, Maffrand, J.P. and Le Fur, G. (2002) Characterization of (2S,4«)-1-[5-Chloro-l-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-li/-indol-3-yl]-4-hydroxy-Ai,Ar-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V,b Receptor Antagonist. J. Pharmacol. Exp. Ther, 300: 1122-1130.

Sgoifo, A, Koolhaas, J, de Boer, S, Musso, E, Stilli, D, Buwalda, B. and Meerlo, P. (1999) Social stress, autonomic neural activation, and cardiac activity in rats. Neurosci. Biobehav. Rev, 23: 915-923.

Steckler, T, Holsboer, F. and Reul, J.M.H.M. (1999) Glucocorticoids and depression. Best. Pract. Res. Clin. Endoc. Met, 13: 597-614.

Steinberg, R, Alonso, R, Griebel, G, Bert, L, Jung, M, Oury-Donat, F, Poncelet, M, Gueudet, C, Desvignes, C, Le Fur, G. and Soubrie, P. (2001) Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J. Pharmacol. Exp. Ther, 299: 449-158.

Stoehr, J.D, Cheng, S.W. and North, W.G. (1993) Homozygous Brattleboro rats display attenuated conditioned freezing responses. Neurosci. Lett, 153: 103-106.

Thibonnier, M, Coles, P, Thibonnier, A. and Shoham, M. (2001) The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu. Rev. Pharmacol. Toxicol, 41: 175-202.

Tribollet, E, Raufaste, D, Maffrand, J. and Serradeil-Le Gal, C. (1999) Binding of the non-peptide vasopressin Vla receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study. Neuroendocr, 69: 113-120.

Vaccari, C, Lolait, S.J. and Ostrowski, N.L. (1998) Comparative distribution of vasopressin Vlb and oxytocin receptor messenger ribonucleic acids in brain. Endocrinol, 139: 5015-5033.

van Leeuwen, F.W. and Caffe, A.R. (1983) Vasopressin-immunoreactive cell bodies in the bed nucleus of the stria terminalis of the rat. Cell Tissue Res, 28: 525-534.

van Londen, L, Goekoop, J.G, van Kempen, G.M.J, Frankhuijzen-Sierevogel, A.C, Wiegant, V.M, Van der Velde, E.A. and De Wied, D. (1997) Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology, 17: 284-292.

Willner, P, Muscat, R. and Papp, M. (1992) An animal model of anhedonia. Clin. Neuropharmacol, 15 Suppl 1 Pt A: 550A-551A.

Young, L.J, Toloczko, D. and Insel, T.R. (1999) Localization of vasopressin (Via) receptor binding and mRNA

in the rhesus monkey brain. J. Neuroendocrinol, 11: 291-297.

Zhou, J.N, Riemersma, R.F, Unmehopa, U.A, Hoogendijk, W.J.G, van Heerikhuize, J.J, Hofman, M.A. and Swaab, D.F. (2001) Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch. Gen. Psychiatry, 58: 655-662.

T. Sleekier, N.H. Kaiin andJ.M.H.M. Reul (Eds.) Handbook of Stress and the Brain, Vol. 15 ISBN 0-444-51823-1

Copyright 2005 Elsevier B.V. All rights reserved

Was this article helpful?

0 0

Post a comment